SCIENTIFIC PROGRAMS
November 2-3 ヒストン脱アセチル化酵素の標的化 GPCRに基づく創薬キナーゼ阻害剤パイプライン癌細胞代謝	November 3-4 機能的スクリーンのためのRNAi アロステリック調節因子 PI3K経路の標的化糖尿病のための創薬

Choose your language

Premier Sponsor

イベントカレンダー

医薬品関連の国際会議

1日目 | 2日目 |

2型糖尿病が世界的に広がりを見せる中、糖尿病のための創薬分野では活発な研究が行われており、後れをとらないためにも多くの議論すべきテーマがあります。2型糖尿病の創薬と薬剤開発分野におけるリスクと進捗について、同業者と議論してください。演壇でのプレゼンテーションや専門家によるパネルディスカッション、討論会などを通じて、次世代の糖尿病治療薬クラス、経口糖尿病治療薬候補の臨床的進捗、インスリン感受性または産生以上に血糖値を下げる標的の有効性、前臨床開発における新たな標的、などのトピックについて話し合います。

11月3日（木）

1:30 pm Chairperson’s Remarks

1:40 FEATURED PRESENTATION:

Inhibiting Glucose Transporters via SGLT inhibitors – the Next New Diabetes Drug Family?

Michael Mark, Ph.D., Vice President, CardioMetabolic Diseases Research, Boehringer Ingelheim

This presentation will provide an update on diabetes drug candidates in late stage development, with a focus on compounds targeting sodium glucose transporters. Current challenges faced in the field of diabetes drug development will also be covered.

2:25 FEATURED PRESENTATION:

Diabetes Drug Targets from Gastric Bypass Surgery

Lee Kaplan Lee M. Kaplan, M.D., Ph.D., Professor, Harvard Medical School

3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 A Physician’s Perspective on the Future of Diabetes Treatments

Rohit N. Kulkarni, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Investigator, Joslin Diabetes Center

This presentation will discuss the scope of the global diabetes problem and which types of diabetes treatments are most needed from a diabetes physician’s and his patients’ perspective to help provide a relevant context to scientists developing new diabetes treatments.

4:15 Sponsored Presentations (Opportunities Available)

4:45 Diabetes Market Landscape

Kelly Close, MBA, President, Close Concerns

5:15 Panel Discussion: Diabetes Drug Development

Moderator: Rebecca Taub, M.D., Senior Vice President, Research and Development, VIA Pharmaceuticals

Developing diabetes drugs in Asia – how is it different? Is that the future?
What will clinical trials look like five years from now?
What is the ideal diabetes treatment regimen?

5:45 End of Day

1日目 | 2日目 |

Suggested Event Package

Nov. 1 Short Courses

(SC2) Biomarkers Ion Channel Assays for Safety Screening - View Agenda

Overview of current and emerging assays and methodologies
Use of automation and high-throughput techniques
Comparison of platforms and applications
Factors affecting sensitivity and specificity

AND

(SC6) Label Free Assays for GPCRs and Safety and Metabolic Profiling - View Agenda

Types of label-free platforms and their pros and cons
Label-free, cell based assays for GPCRs
Tyrosine kinase-based label free assays for selectivity considerations
Metabolic profiling applications (measuring pH and oxygen consumption changes)

Nov. 2-3 Conferences

Cancer Cell Metabolism

Or

GPCR-Based Drug Discovery

Nov. 3 Short Course

(SC9) Dinner Course: Targeting Pancreatic Islets for Type 2 Diabetes - View Agenda

In recent years, ways to regenerate the beta islet cells of the pancreas, the producers of insulin, have been of great interest to scientists searching for new ways to treat diabetes. This course will review the basics of the role of the pancreas in diabetes and cover the current progress being made and challenges to overcome for developing therapies directed at regenerating pancreatic beta cells.

Nov 3-4

Diabetes Drug Discovery